Psychedelics, also known as classical hallucinogens, have been investigated for decades
due to their potential therapeutic effects in the treatment of neuropsychiatric and substance …

Psychedelics make up a group of psychoactive compounds that induce hallucinogenic
effects by activating the serotonin 2A receptor (5-HT2AR). Clinical trials have demonstrated …

Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT2A
receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5 …

Hallucinations limit widespread therapeutic use of psychedelics as rapidly acting
antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) …

Psychedelic compounds have shown extraordinary potential in treating a wide range of
neuropsychiatric disorders. Psilocybin, for example, has now been shown in several clinical …

Alcohol abuse is a leading risk factor for the public health burden worldwide. Approved
pharmacotherapies have demonstrated limited effectiveness over the last few decades in …

MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a
distinct therapeutic mechanism due to its unique pharmacology and subjective effects …

Primary metabolites of mushroom tryptamines, psilocybin and baeocystin (ie, psilocin and
norpsilocin), exhibit potent agonist activity at the serotonin 2A receptor (5-HT2A) in vitro but …

Analogues of 4-phosphoryloxy-N, N-dimethyltryptamine (psilocybin) are being sold on
recreational drug markets and developed as potential medications for psychedelic-assisted …

Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a
hallucinatory effect through serotonin 5-HT2A receptor (5-HT2A) activation. Recent studies …